KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Exchange Rate Effect (2016 - 2025)

Vertex Pharmaceuticals has reported Exchange Rate Effect over the past 17 years, most recently at $7.3 million for Q4 2025.

  • Quarterly results put Exchange Rate Effect at $7.3 million for Q4 2025, up 115.43% from a year ago — trailing twelve months through Dec 2025 was $90.9 million (up 313.38% YoY), and the annual figure for FY2025 was $90.9 million, up 313.38%.
  • Exchange Rate Effect for Q4 2025 was $7.3 million at Vertex Pharmaceuticals, up from -$4.1 million in the prior quarter.
  • Over the last five years, Exchange Rate Effect for VRTX hit a ceiling of $57.2 million in Q2 2025 and a floor of -$47.3 million in Q4 2024.
  • Median Exchange Rate Effect over the past 5 years was -$3.2 million (2021), compared with a mean of $1.6 million.
  • Biggest five-year swings in Exchange Rate Effect: tumbled 747.5% in 2022 and later soared 2388.0% in 2025.
  • Vertex Pharmaceuticals' Exchange Rate Effect stood at -$4.9 million in 2021, then surged by 932.65% to $40.8 million in 2022, then plummeted by 32.84% to $27.4 million in 2023, then plummeted by 272.63% to -$47.3 million in 2024, then surged by 115.43% to $7.3 million in 2025.
  • The last three reported values for Exchange Rate Effect were $7.3 million (Q4 2025), -$4.1 million (Q3 2025), and $57.2 million (Q2 2025) per Business Quant data.